Sutro Biopharma Inc (STRO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$20.07-2.29%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Revenue decline slows to less than -10% YoY: FY27 rev -38.8% vs >-10% target.
Sutro Biopharma is cutting costs to improve its losses. Operating loss was $29.66M in 2026-Q1. The company ended its ATM stock sale program to focus on financial health. Analysts expect revenue to stabilize after sharp declines.
The company keeps losing money with no clear profit path. Revenue is expected to drop over 50% next year. Cost cuts may not be enough to fix financial problems.
The price is about 56% below our fair value near $73. Analysts expect revenue to fall about 54%. Our fair value is well above the Street median near $50.
Breaks if: operating loss worsens beyond -$30M
Management is focused on managing operating expenses to improve financial performance.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making, and while it has a promising pipeline, the execution risks and recent earnings misses create uncertainty.
The market appears to have priced in a low expectations gap, suggesting that investors are not overly optimistic about STRO's near-term performance. Compared to peers, STRO is viewed as cheap, but the fundamentals indicate significant risks.
Management is focused on advancing clinical developments and maintaining a cash position, but recent cash declines and mixed progress on operating expenses raise concerns. The company has a medium confidence level in its ability to meet its operational goals.
Key factors include the company's ability to avoid further earnings misses and the performance of sector leaders, which could influence sentiment in the healthcare space. Additionally, economic indicators like job reports may impact STRO's performance.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has negatively impacted the outlook. This miss confirms ongoing challenges in revenue performance, which is a key concern for the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue decline worse than -10% YoY
Breaks if: ATM program restarted or new dilution program announced
In the next 1-3 years, STRO's trajectory will depend on clinical advancements and market conditions. Not investment advice.